المؤلفون: Hendriks, L. E., Kerr, K. M., Menis, J., Mok, T. S., Nestle, U., Passaro, A., Peters, S., Planchard, D., Smit, E. F., Solomon, B. J., Veronesi, G., Reck, M., Guidelines Committee, ESMO

المصدر: Hendriks , L E , Kerr , K M , Menis , J , Mok , T S , Nestle , U , Passaro , A , Peters , S , Planchard , D , Smit , E F , Solomon , B J , Veronesi , G , Reck , M , ESMO Guidelines Committee & Guidelines Committee , ESMO 2023 , ' Oncogene-addicted metastatic non-small-cell lung cancer : ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ' , Annals of Oncology , vol. 34 , no. 4 , pp. 339-357 . https://doi.org/10.1016/j.annonc.2022.12.009Test

مصطلحات موضوعية: ESCAT, ESMO Clinical Practice Guideline (CPG), ESMO-MCBS, oncogene-addicted metastatic non-small-cell lung cancer (mNSCLC), treatment, targeted therapy, TYROSINE KINASE INHIBITORS, PROGRESSION-FREE SURVIVAL, RESPONSE EVALUATION CRITERIA, FACTOR RECEPTOR MUTATIONS, OPEN-LABEL, 1ST-LINE TREATMENT, SINGLE-ARM, TREATMENT-NAIVE, EGFR MUTATIONS, ADVANCED NSCLC

وصف الملف: application/pdf

العلاقة: https://cris.maastrichtuniversity.nl/en/publications/a6c20759-e209-411f-b9b7-789fc32e2f64Test

الإتاحة: https://doi.org/10.1016/j.annonc.2022.12.009Test
https://cris.maastrichtuniversity.nl/en/publications/a6c20759-e209-411f-b9b7-789fc32e2f64Test
https://cris.maastrichtuniversity.nl/ws/files/192165782/Hendriks-2023-Oncogene-addicted-metastatic-non-small.pdfTest

المؤلفون: Hendriks, L. E., Kerr, K. M., Menis, J., Mok, T. S., Nestle, U., Passaro, A., Planchard, D., Peters, S., Smit, E. F., Solomon, B. J., Veronesi, G., Reck, M., Guidelines Committee, ESMO

المصدر: Hendriks , L E , Kerr , K M , Menis , J , Mok , T S , Nestle , U , Passaro , A , Planchard , D , Peters , S , Smit , E F , Solomon , B J , Veronesi , G , Reck , M , ESMO Guidelines Committee & Guidelines Committee , ESMO 2023 , ' Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ' , Annals of Oncology , vol. 34 , no. 4 , pp. 358-376 . https://doi.org/10.1016/j.annonc.2022.12.013Test

مصطلحات موضوعية: ESCAT, ESMO Clinical Practice Guideline (CPG), ESMO-MCBS, non-oncogene-addicted metastatic non-small-cell lung cancer (mNSCLC), treatment, targeted therapy, immunotherapy, RANDOMIZED PHASE-III, QUALITY-OF-LIFE, PACLITAXEL DOUBLET CHEMOTHERAPY, RESPONSE EVALUATION CRITERIA, PLATINUM-BASED CHEMOTHERAPY, PEMETREXED PLUS CISPLATIN, SPECIFIED FINAL ANALYSIS, INDIVIDUAL PATIENT DATA, ELDERLY-PATIENTS, 2ND-LINE TREATMENT

وصف الملف: application/pdf

العلاقة: https://cris.maastrichtuniversity.nl/en/publications/7f71c7db-b119-4345-a38e-5b383cefe585Test

الإتاحة: https://doi.org/10.1016/j.annonc.2022.12.013Test
https://cris.maastrichtuniversity.nl/en/publications/7f71c7db-b119-4345-a38e-5b383cefe585Test
https://cris.maastrichtuniversity.nl/ws/files/192165470/Hendriks-2023-Non-oncogene-addicted-metastatic-non.pdfTest

المؤلفون: Gosney, J R, Paz-Ares, L, Jänne, P, Kerr, K M, Leighl, N B, Lozano, M D, Malapelle, U, Mok, T, Sheffield, B S, Tufman, A, Wistuba, I I, Peters, S

المساهمون: Gosney, J R, Paz-Ares, L, Jänne, P, Kerr, K M, Leighl, N B, Lozano, M D, Malapelle, U, Mok, T, Sheffield, B S, Tufman, A, Wistuba, I I, Peters, S

مصطلحات موضوعية: NSCLC, molecular pathology, non-small-cell lung cancer, predictive biomarker, reflex testing, turnaround time

العلاقة: info:eu-repo/semantics/altIdentifier/wos/WOS:001040711700001; volume:8; issue:4; firstpage:101587; journal:ESMO OPEN; https://hdl.handle.net/11588/929064Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85162976928

الإتاحة: https://doi.org/10.1016/j.esmoop.2023.101587Test
https://hdl.handle.net/11588/929064Test

المؤلفون: Letovanec I., Finn S., Zygoura P., Smyth P., Soltermann A., Bubendorf L., Speel E. -J. M., Marchetti A., Nonaka D., Monkhorst K., Hager H., Martorell M., Sejda A., Cheney R., Hernandez-Losa J., Verbeken E., Weder W., Savic S., Di Lorito A., Navarro A., Felip E., Warth A., Baas P., Meldgaard P., Blackhall F., Dingemans A. -M., Dienemann H., Dziadziuszko R., Vansteenkiste J., O'Brien C., Geiger T., Sherlock J., Schageman J., Dafni U., Kammler R., Kerr K. M., Thunnissen E., Stahel R. A., Peters S., Rosell R., Molina M. A., Hiltbrunner A., Marti N., Tsourti Z., Polydoropoulou V., Gray S., Opitz I., Curioni A., Lardinois D., Ruland A., De Luca G.

المساهمون: Letovanec, I., Finn, S., Zygoura, P., Smyth, P., Soltermann, A., Bubendorf, L., Speel, E. -J. M., Marchetti, A., Nonaka, D., Monkhorst, K., Hager, H., Martorell, M., Sejda, A., Cheney, R., Hernandez-Losa, J., Verbeken, E., Weder, W., Savic, S., Di Lorito, A., Navarro, A., Felip, E., Warth, A., Baas, P., Meldgaard, P., Blackhall, F., Dingemans, A. -M., Dienemann, H., Dziadziuszko, R., Vansteenkiste, J., O'Brien, C., Geiger, T., Sherlock, J., Schageman, J., Dafni, U., Kammler, R., Kerr, K. M., Thunnissen, E., Stahel, R. A., Peters, S., Rosell, R., Molina, M. A., Hiltbrunner, A., Marti, N., Tsourti, Z., Polydoropoulou, V., Gray, S., Opitz, I., Curioni, A., Lardinois, D., Ruland, A., De Luca, G.

مصطلحات موضوعية: ALK, NGS, NSCLC, RT-PCR, Anaplastic Lymphoma Kinase, Carcinoma, Non-Small-Cell Lung, Cohort Studie, Europe, Female, High-Throughput Nucleotide Sequencing, Human, Lung Neoplasm, Male, Reverse Transcriptase Polymerase Chain Reaction, Thoracic Neoplasms

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/29191776; info:eu-repo/semantics/altIdentifier/wos/WOS:000429213700021; volume:13; issue:3; firstpage:413; lastpage:425; numberofpages:13; journal:JOURNAL OF THORACIC ONCOLOGY; http://hdl.handle.net/11564/712077Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85041242224; https://www.journals.elsevier.com/journal-of-thoracic-oncologyTest/

الإتاحة: https://doi.org/10.1016/j.jtho.2017.11.117Test
http://hdl.handle.net/11564/712077Test
https://www.journals.elsevier.com/journal-of-thoracic-oncologyTest/

المؤلفون: Al Bakir, M., Huebner, A., Martinez-Ruiz, C., Grigoriadis, K., Watkins, T. B. K., Pich, O., Moore, D. A., Veeriah, S., Ward, S., Laycock, J., Johnson, D., Rowan, A., Razaq, M., Akther, M., Naceur-Lombardelli, C., Prymas, P., Toncheva, A., Hessey, S., Dietzen, M., Colliver, E., Frankell, A. M., Bunkum, A., Lim, E. L., Karasaki, T., Abbosh, C., Hiley, C. T., Hill, M. S., Cook, D. E., Wilson, G. A., Salgado, R., Nye, E., Stone, R. K., Fennell, D. A., Price, G., Kerr, K. M., Naidu, B., Middleton, G., Summers, Yvonne J, Lindsay, Colin R, Blackhall, Fiona H, Cave, J., Blyth, K. G., Nair, A., Ahmed, A., Taylor, M. N., Procter, A. J., Falzon, M., Lawrence, D., Navani, N., Thakrar, R. M., Janes, S. M., Papadatos-Pastos, D., Forster, M. D., Lee, S. M., Ahmad, T., Quezada, S. A., Peggs, K. S., Van Loo, P., Dive, Caroline, Hackshaw, A., Birkbak, N. J., Zaccaria, S., Jamal-Hanjani, M., McGranahan, N., Swanton, C., Lester, J. F., Bajaj, A., Nakas, A., Sodha-Ramdeen, A., Ang, K., Tufail, M., Chowdhry, M. F., Scotland, M., Boyles, R., Rathinam, S., Wilson, C., Marrone, D., Dulloo, S., Matharu, G., Shaw, J. A., Riley, J., Primrose, L., Boleti, E., Cheyne, H., Khalil, M., Richardson, S., Cruickshank, T., Benafif, S., Gilbert, K., Patel, A. J., Osman, A., Lacson, C., Langman, G., Shackleford, H., Djearaman, M., Kadiri, S., Leek, A., Hodgkinson, J. D., Totten, N., Montero, A., Smith, E., Fontaine, E., Granato, F., Doran, H., Novasio, J., Rammohan, K., Joseph, L., Bishop, P., Shah, R., Moss, S., Joshi, V., Crosbie, P., Gomes, F., Brown, K., Carter, M., Chaturvedi, A., Priest, L., Oliveira, P., Krebs, M. G., Clipson, A., Tugwood, J., Kerr, A., Rothwell, D. G., Kilgour, E., Aerts, H., Schwarz, R. F., Kaufmann, T. L., Rosenthal, R., Szallasi, Z., Kisistok, J., Sokac, M., Diossy, M., Demeulemeester, J., Stewart, A., Magness, A., Karamani, A., Chain, B., Campbell, B. B., Castignani, C., Bailey, C., Puttick, C., Weeden, C. E., Lee, C., Richard, C., Pearce, D. R., Karagianni, D., Biswas, D., Levi, D., Hoxha, E., Cadieux, E. L., Gronroos, E., Galvez-Cancino, F., Athanasopoulou, F., Gimeno-Valiente, F., Kassiotis, G., Stavrou, G., Mastrokalos, G., Zhai, H. R., Lowe, H. L., Matos, I., Goldman, J., Reading, J. L., Black, J. R. M., Herrero, J., Rane, J. K., Nicod, J., Lam, J. M., Hartley, J. A., Enfield, K. S. S., Selvaraju, K., Thol, K., Litchfield, K., Ng, K. W., Chen, K. Z., Dijkstra, K., Thakkar, K., Ensell, L., Shah, M., Vasquez, M., Litovchenko, M., Sunderland, M. W., Leung, M., Escudero, M., Angelova, M., Tanic, M., Sivakumar, M., Kanu, N., Chervova, O., Lucas, O., Al-Sawaf, O., Hobson, P., Pawlik, P., Bentham, R., Hynds, R. E., Vendramin, R., Saghafinia, S., Lopez, S., Gamble, S., Ung, S. K. A., Vanloo, S., Boeing, S., Beck, S., Bola, S. K., Denner, T., Marafioti, T., Mourikis, T. P., Spanswick, V., Barbe, V., Lu, W. T., Hill, W., Liu, W. K., Wu, Y., Naito, Y., Ramsden, Z., Veiga, C., Royle, G., Collins-Fekete, C. A., Fraioli, F., Ashford, P., Clark, T., Borg, E., Wilson, J., Patrini, D., Hoogenboom, E. M., Monk, F., Holding, J. W., Choudhary, J., Bhakhri, K., Scarci, M., Hayward, M., Panagiotopoulos, N., Gorman, P., Khiroya, R., Stephens, R. C. M., Wong, Y. N. S., Bandula, S., Sharp, A., Smith, S., Gower, N., Dhanda, H. K., Chan, K., Pilotti, C., Leslie, R., Grapa, A., Zhang, H. Y., AbdulJabbar, K., Pan, X. X., Yuan, Y. Y., Chuter, D., MacKenzie, M., Chee, S., Alzetani, A., Scarlett, L., Richards, J., Ingram, P., Austin, S., Lim, E., De Sousa, P., Jordan, S., Rice, A., Raubenheimer, H., Bhayani, H., Ambrose, L., Devaraj, A., Chavan, H., Begum, S., Buderi, S. I., Kaniu, D., Malima, M., Booth, S., Nicholson, A. G., Fernandes, N., Shah, P., Proli, C., Hewish, M., Danson, S., Shackcloth, M. J., Robinson, L., Russell, P., Dick, C., Le Quesne, J., Kirk, A., Asif, M., Bilancia, R., Kostoulas, N., Thomas, M.

المساهمون: Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London

العلاقة: https://dx.doi.org/10.1038/s41586-023-05729-xTest; Al Bakir M, Huebner A, Martinez-Ruiz C, Grigoriadis K, Watkins TBK, Pich O, et al. The evolution of non-small cell lung cancer metastases in TRACERx. Nature. 2023 2023 Apr. PubMed PMID: WOS:000991048500004.; http://hdl.handle.net/10541/626391Test; Nature

الإتاحة: https://doi.org/10.1038/s41586-023-05729-xTest
http://hdl.handle.net/10541/626391Test

المؤلفون: Frankell, A. M., Dietzen, M., Al Bakir, M., Lim, E. L., Karasaki, T., Ward, S., Veeriah, S., Colliver, E., Huebner, A., Bunkum, A., Hill, M. S., Grigoriadis, K., Moore, D. A., Black, J. R. M., Liu, W. K., Thol, K., Pich, O., Watkins, T. B. K., Naceur-Lombardelli, C., Cook, D. E., Salgado, R., Wilson, G. A., Bailey, C., Angelova, M., Bentham, R., Martínez-Ruiz, C., Abbosh, C., Nicholson, A. G., Le Quesne, J., Biswas, D., Rosenthal, R., Puttick, C., Hessey, S., Lee, C., Prymas, P., Toncheva, A., Smith, J., Xing, W., Nicod, J., Price, G., Kerr, K. M., Naidu, B., Middleton, G., Blyth, K. G., Fennell, D. A., Forster, M. D., Lee, S. M., Falzon, M., Hewish, M., Shackcloth, M. J., Lim, E., Benafif, S., Russell, P., Boleti, E., Krebs, Matthew G, Lester, J. F., Papadatos-Pastos, D., Ahmad, T., Thakrar, R. M., Lawrence, D., Navani, N., Janes, S. M., Dive, Caroline, Blackhall, Fiona H, Summers, Yvonne J, Cave, J., Marafioti, T., Herrero, J., Quezada, S. A., Peggs, K. S., Schwarz, R. F., Van Loo, P., Miedema, D. M., Birkbak, N. J., Hiley, C. T., Hackshaw, A., Zaccaria, S., Jamal-Hanjani, M., McGranahan, N., Swanton, C.

المساهمون: Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK

العلاقة: https://dx.doi.org/10.1038/s41586-023-05783-5Test; Frankell AM, Dietzen M, Al Bakir M, Lim EL, Karasaki T, Ward S, et al. The evolution of lung cancer and impact of subclonal selection in TRACERx. Nature. 2023 Apr;616(7957):525-33. PubMed PMID: 37046096. Pubmed Central PMCID: PMC10115649 for tumour monitoring (PCT/EP2022/077987). M.A.B. has consulted for Achilles Therapeutics. D.A.M. reports speaker fees from AstraZeneca, Eli Lilly and Takeda, consultancy fees from AstraZeneca, Thermo Fisher, Takeda, Amgen, Janssen, MIM Software, Bristol-Myers Squibb (BMS) and Eli Lilly and has received educational support from Takeda and Amgen. S.V. is a co-inventor on a patent to detect molecules in a sample (US patent 10578620). G.A.W. is employed by and has stock options in Achilles Therapeutics. R.S. reports non-financial support from Merck and BMS, research support from Merck, Puma Biotechnology and Roche, and personal fees from Roche, BMS and Exact Sciences for advisory boards. C.A. has received speaking honoraria or expenses from Novartis, Roche, AstraZeneca and BMS and reports employment at AstraZeneca. C.A. is an inventor on a European patent application relating to assay technology to detect tumour recurrence (PCT/GB2017/053289); the patent has been licensed to commercial entities and under their terms of employment, C.A. is due a revenue share of any revenue generated from such licence(s). C.A. declares a patent application (PCT/US2017/028013) for methods to detect lung cancer. C.A. is a named inventor on a patent application to determine methods and systems for tumour monitoring (PCT/EP2022/077987). C.A. is a named inventor on a provisional patent protection related to a ctDNA detection algorithm. D.B. reports personal fees from NanoString and AstraZeneca. He has a patent (PCT/GB2020/050221) issued on methods for cancer prognostication. R.R. is an employee of and has stock options in Achilles Therapeutics and holds a European patent on targeting neoantigens (PCT/EP2016/059401) and in determining HLA LOH (PCT/GB2018/052004). D.A.F. reports grants from Aldeyra, Boehringer Ingelheim, Astex Therapeutics, Bayer, BMS, GSK, RS Oncology, Clovis, Eli Lilly, MSD, GSK, personal fees from Atara, BMS, Boehringer Ingelheim, Cambridge Clinical Laboratories, Targovax, Roche and RS Oncology. M.D.F. acknowledges grant support from CRUK, AstraZeneca, Boehringer Ingelheim, MSD and Merck; is an advisory board member for Transgene; and has consulted for Achilles, Amgen, AstraZeneca, Bayer, Boxer, BMS, Celgene, EQRx, Guardant Health, Immutep, Ixogen, Janssen, Merck, MSD, Nanobiotix, Novartis, Oxford VacMedix, Pharmamar, Pfizer, Roche, Takeda and UltraHuman. K.S.P. is a co-founder of Achilles Therapeutics. S.A.Q. is a co-founder, stockholder and Chief Scientific Officer of Achilles Therapeutics. E.L. has received funding from AstraZeneca, Boehringer Ingelheim, Medela, Johnson & Johnson/Ethicon, Covidien/Medtronic, Guardant Health, Takeda, Lilly Oncology, Boehringer Ingelheim and Bayer. E.L. has received consulting fees from Beigene, Roche and BMS, honoraria from Medela and is a founder My Cancer Companion, Healthcare Companion Ltd. N.N. reports honoraria for non-promotional educational talks, advisory boards or conference attendance from Amgen, AstraZeneca, Boehringer Ingelheim, BMS, Fujifilm, Guardant Health, Intuitive, Janssen, Lilly, Merck Sharp & Dohme, Olympus, OncLive, PeerVoice, Pfizer and Takeda. S.M.J. has received fees for advisory board membership in the past 3 years from AstraZeneca, Bard1 Lifescience and Johnson & Johnson. He has received a grant income from Owlstone and GRAIL Inc. He has received assistance with travel to an academic meeting from Cheisi. C.D. has received research funding and educational research grants from AstraZeneca, Astex Pharmaceuticals, Bioven, Amgen, Carrick Therapeutics, Merck, Taiho Oncology, GSK, Bayer, Boehringer Ingelheim, Roche, BMS, Novartis, Celgene, Epigene Therapeutics, Angle PLC, Menarini, Clearbridge Biomedics, Thermo Fisher Scientific and Neomed Therapeutics. C.D. has also received honoraria for consultancy and/or advisory boards from Biocartis, Merck, AstraZeneca, GRAIL and Boehringer Ingelheim. J.C. reports funding from Amgen to attend a conference. A. Hackshaw has received fees for being a member of Independent Data Monitoring Committees for Roche-sponsored clinical trials, and academic projects co-ordinated by Roche. N.J.B. is a co-inventor on a patent to identify responders to cancer treatment (PCT/GB2018/051912), has a patent application (PCT/GB2020/050221) on methods for cancer prognostication and is a co-inventor on a patent for methods for predicting anticancer responses (US14/466,208). C.T.H. has received speaker fees from AstraZeneca. M.J.-H. has consulted for and is a member of the Achilles Therapeutics Scientific Advisory Board (SAB) and Steering Committee, has received speaker honoraria from Pfizer, Astex Pharmaceuticals, Oslo Cancer Cluster, and holds a patent (PCT/US2017/028013) relating to methods for lung cancer detection. This patent has been licensed to commercial entities and under terms of employment, M.J.-H. is due a share of any revenue generated from such licence(s). N.M. has received consultancy fees and has stock options in Achilles Therapeutics. N.M. holds European patents relating to targeting neoantigens (PCT/EP2016/059401), identifying patient response to immune checkpoint blockade (PCT/EP2016/071471), determining HLA LOH (PCT/GB2018/052004) and predicting survival rates of patients with cancer (PCT/GB2020/050221). C.S. acknowledges grant support from AstraZeneca, Boehringer-Ingelheim, BMS, Pfizer, Roche-Ventana, Invitae (previously Archer Dx (collaboration in minimal residual disease sequencing technologies)) and Ono Pharmaceutical. C.S. is an AstraZeneca Advisory Board member and Chief Investigator for the AZ MeRmaiD 1 and 2 clinical trials and is also Co-Chief Investigator of the NHS Galleri trial funded by GRAIL and a paid member of GRAIL’s SAB. He receives consultant fees from Achilles Therapeutics (also a SAB member), Bicycle Therapeutics (also a SAB member), Genentech, Medicxi, Roche Innovation Centre–Shanghai, Metabomed (until July 2022), and the Sarah Cannon Research Institute. C.S. had stock options in Apogen Biotechnologies and GRAIL until June 2021, and currently has stock options in Epic Bioscience, Bicycle Therapeutics, and has stock options and is co-founder of Achilles Therapeutics. C.S. is an inventor on a European patent application relating to an assay technology to detect tumour recurrence (PCT/GB2017/053289), the patent has been licensed to commercial entities and under his terms of employment, C.S. is due a revenue share of any revenue generated from such licence(s). C.S. holds patents relating to targeting neoantigens (PCT/EP2016/059401), identifying patient responses to immune checkpoint blockade (PCT/EP2016/071471), determining HLA LOH (PCT/GB2018/052004), predicting survival rates of patients with cancer (PCT/GB2020/050221), identifying patients who respond to cancer treatment (PCT/GB2018/051912), a US patent relating to detecting tumour mutations (PCT/US2017/28013), methods for lung cancer detection (US20190106751A1) and both a European and US patent related to identifying indel mutation targets (PCT/GB2018/051892) and is a co-inventor on a patent application to determine methods and systems for tumour monitoring (PCT/EP2022/077987). C.S. is a named inventor on a provisional patent related to a ctDNA detection algorithm. Epub 2023/04/13. eng.; http://hdl.handle.net/10541/626225Test; Nature

الإتاحة: https://doi.org/10.1038/s41586-023-05783-5Test
http://hdl.handle.net/10541/626225Test

المؤلفون: Kerr, K M, Dafni, U, Schulze, K, Thunnissen, E, Bubendorf, L, Hager, H, Finn, S, Biernat, W, Vliegen, L, Losa, J H, Marchetti, A, Cheney, R, Warth, A, Speel, Ernst-Jan, Blackhall, F, Monkhorst, K, Jantus Lewintre, E, Tischler, V, Clark, C, Bertran-Alamillo, J, Meldgaard, P, Gately, K, Wrona, A, Vandenberghe, P, Felip, E, De Luca, G, Savic, S, Muley, T, Smit, E F, Dingemans, A-M C, Priest, L, Baas, P, Camps, C, Weder, W, Polydoropoulou, V, Geiger, T R, Kammler, R, Sumiyoshi, T, Molina, M A, Shames, D S, Stahel, R A, Peters, S

المصدر: Kerr , K M , Dafni , U , Schulze , K , Thunnissen , E , Bubendorf , L , Hager , H , Finn , S , Biernat , W , Vliegen , L , Losa , J H , Marchetti , A , Cheney , R , Warth , A , Speel , E-J , Blackhall , F , Monkhorst , K , Jantus Lewintre , E , Tischler , V , Clark , C , Bertran-Alamillo , J , Meldgaard , P , Gately , K , Wrona , A , Vandenberghe , P , ....

العلاقة: https://research.vumc.nl/en/publications/2bf59980-0a5a-4fa9-ab3f-c4c706300e92Test

الإتاحة: https://doi.org/10.1093/annonc/mdx629Test
https://research.vumc.nl/en/publications/2bf59980-0a5a-4fa9-ab3f-c4c706300e92Test

المؤلفون: Williams, G. H., Nicholson, A. G., Snead, D. R.J., Thunnissen, E., Lantuejoul, S., Cane, P., Kerr, K. M., Loddo, M., Scott, M., Scorer, P. W., Barker, C.

المصدر: Williams , G H , Nicholson , A G , Snead , D R J , Thunnissen , E , Lantuejoul , S , Cane , P , Kerr , K M , Loddo , M , Scott , M , Scorer , P W & Barker , C 2018 , ' Inter-rater reliability of programmed death ligand 1 (PD-L1) scoring using the VENTANA PD-L1 (SP263) assay in non-small cell lung cancer (NSCLC) ' , Annals of oncology : official journal of the European Society for Medical Oncology , vol. 29 , pp. viii49 . https://doi.org/10.1093/annonc/mdy269.153Test

العلاقة: https://research.vumc.nl/en/publications/50d27b52-8fd5-40bf-936f-d0727df8cc3aTest

الإتاحة: https://doi.org/10.1093/annonc/mdy269.153Test
https://research.vumc.nl/en/publications/50d27b52-8fd5-40bf-936f-d0727df8cc3aTest
http://www.scopus.com/inward/record.url?scp=85081531174&partnerID=8YFLogxKTest

المؤلفون: Woolhouse, I., Bishop, L., Darlison, Liz, de Fonseka, D., Edey, A., Edwards, J., Faivre-Finn, C., Fennell, Dean A., Holmes, S., Kerr, K. M., Nakas, Apostolos, Peel, T., Rahman, N. M., Slade, M., Steele, J., Tsim, S., Maskell, N. A.

مصطلحات موضوعية: mesothelioma

العلاقة: https://www.ncbi.nlm.nih.gov/pubmed/29531746Test; BMJ Open Respiratory Research, 2018, 5 (1), e000266; http://bmjopenrespres.bmj.com/content/5/1/e000266.infoTest; http://hdl.handle.net/2381/41514Test; bmjresp-2017-000266

الإتاحة: https://doi.org/10.1136/bmjresp-2017-000266Test
http://bmjopenrespres.bmj.com/content/5/1/e000266.infoTest
http://hdl.handle.net/2381/41514Test

المؤلفون: Bonomi, P D, Gandara, D, Hirsch, F R, Kerr, K M, Obasaju, C, Paz Ares, Luis Gonzaga, Bellomo, C, Bradley, J D, Bunn, P A, Culligan, M, Jett, J R, Kim, E S, Langer, C J, Natale, R B, Novello, S, Pérol, M, Ramalingam, S S, Reck, M, Reynolds, C H, Smit, E F, Socinski, M A, Spigel, D R, Vansteenkiste, J F, Wakelee, H, Thatcher, N

المساهمون: Fundación Lilly

مصطلحات موضوعية: GROWTH-FACTOR RECEPTOR, PHASE-III TRIAL, CLINICAL-PRACTICE GUIDELINES, CISPLATIN PLUS GEMCITABINE, OPEN-LABEL, STAGE IV, 1ST-LINE THERAPY, FOLLOW-UP, CETUXIMAB, CHEMOTHERAPY

العلاقة: https://doi.org/10.1093/annonc/mdy196Test.; Ann Oncol. 2018; 29(8):1701-1709.; http://hdl.handle.net/20.500.12105/6820Test; Annals of oncology : official journal of the European Society for Medical Oncology

الإتاحة: https://doi.org/20.500.12105/6820Test
https://doi.org/10.1093/annonc/mdy196Test
https://hdl.handle.net/20.500.12105/6820Test